Latest Breaking News On - Fusion pharmaceuticals price performance - Page 3 : comparemela.com

Fusion Pharmaceuticals (NASDAQ:FUSN) Hits New 52-Week High at $10 64

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report)’s share price hit a new 52-week high on Thursday . The stock traded as high as $10.64 and last traded at $10.30, with a volume of 223577 shares changing hands. The stock had previously closed at $10.03. Analysts Set New Price Targets A number of equities research […]

United statesWilliam blairFusion pharmaceuticals price performanceNews ratings for fusion pharmaceuticals dailyHermes incPerceptive advisorsRoyal bankFusion pharmaceuticalsFusion pharmaceuticals incSphera funds managementEagle health investmentsGet free reportBloom burtonFunds managementPharmaceuticals incFusion pharmaceuticals daily

Fusion Pharmaceuticals (NASDAQ:FUSN) Shares Gap Down to $9 12

Fusion Pharmaceuticals (NASDAQ:FUSN) Shares Gap Down to $9 12
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesRaymond jamesWilliam blairNews ratings for fusion pharmaceuticals dailyFusion pharmaceuticals price performanceSphera funds managementPerceptive advisorsHermes incHedge funds weigh in on fusion pharmaceuticalsFusion pharmaceuticalsFusion pharmaceuticals incGet free reportPartners managementFunds managementPharmaceuticals incFusion pharmaceuticals daily

Fusion Pharmaceuticals (NASDAQ:FUSN) Price Target Increased to $15 00 by Analysts at Oppenheimer

Fusion Pharmaceuticals (NASDAQ:FUSN) Price Target Increased to $15 00 by Analysts at Oppenheimer
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United statesRaymond jamesRenaissance technologiesInstitutional investors weigh in on fusion pharmaceuticalsNews ratings for fusion pharmaceuticals dailyRoyal bankFusion pharmaceuticalsAnalyst recommendations for fusion pharmaceuticalsCitadel advisorsFusion pharmaceuticals price performanceForefront analyticsFusion pharmaceuticals incSchonfeld strategic advisorsMillennium managementGet free reportStrategic advisors

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) Expected to Post Q4 2023 Earnings of ($0 36) Per Share

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) Expected to Post Q4 2023 Earnings of ($0 36) Per Share
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesRaymond jamesEagle health investmentsFusion pharmaceuticals price performanceNews ratings for fusion pharmaceuticals dailyHermes incFusion pharmaceuticals incFusion pharmaceuticalsSphera funds managementPerceptive advisorsFree reportFusion pharmaceuticalGet free reportFunds managementPharmaceuticals incFusion pharmaceuticals daily

Wedbush Weighs in on Fusion Pharmaceuticals Inc s Q3 2023 Earnings (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Analysts at Wedbush boosted their Q3 2023 EPS estimates for Fusion Pharmaceuticals in a note issued to investors on Wednesday, August 9th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.38) per share for the quarter, up from their prior estimate of ($0.43). The […]

United statesRaymond jamesFusion pharmaceuticals price performanceInstitutional investors weigh in on fusion pharmaceuticalsNews ratings for fusion pharmaceuticals dailyHermes incRenaissance technologiesCitadel advisorsFusion pharmaceuticalsFusion pharmaceuticals incFusion pharmaceuticals company profileMillennium managementFree reportFusion pharmaceuticalGet free reportPharmaceuticals inc